If interested in sponsoring the 2024 conference, please reach out to Ashley Williams, ashleylw@stanford.edu.
If interested in sponsoring the 2024 conference, please reach out to Ashley Williams, ashleylw@stanford.edu.
OHSU is an equal opportunity affirmative action institution.
© 2024 Canary Center at Stanford, OHSU Knight Cancer Institute, and Cancer Research UK
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ:ILMN) currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission. For more information, visit grail.com.
This will close in 0 seconds
Detection of solid tumours at the early stage is associated with a better possibility of cure and survival. In addition, minimally invasive cancer tests that provide patient-specific, comprehensive treatment options can bring meaningful outcomes for treating and monitoring advanced/ refractory/ rare cancers. Datar Cancer Genetics UK Private Limited (DCG) has unique value portfolio that offers all of the above. Our liquid biopsy tests span across multicancer screening, early detection, comprehensive therapy recommendation, and cancer monitoring. These tests are performed in DCG UK’s fully accredited and equipped laboratory space, needing clients only to send the blood samples in DCG-provided blood collection kits. We deliver the comprehensive results within 10-12 working days. Our tests are CE-marked, IVD regulated under directive 98/79/EC. Our laboratory facility is CAP and CLIA accredited, working under ISO15189 QMS and is located at the Surrey Research Park, Guildford, United Kingdom.
DCG UK offers innovative tests for screening and diagnosis of solid organ cancers cancer based on detecting the presence of Circulating Tumour Cells (CTCs). CTCs are malignant cells shed by tumors into the vasculature and are a potent analyte for non-invasive diagnosis of cancer. DCG has a novel approach for the negative enrichment of CTCs from peripheral blood samples with proprietary chemistry that selectively kills non-malignant cells to enrich the desired CTCs, enhancing the clinical sensitivity. We combine our propriety CTC based technology and the power of genomics to provide solutions to various stages of cancer diagnosis and management.
For more details on the technology and publications, please visit: https://uk.datarpgx.com/
This will close in 0 seconds
Elypta is a Swedish cancer detection company focused on reducing cancer mortality by enabling earlier detection and improved monitoring.
The metabolism-based liquid biopsy platform in development measures a novel panel of biomarkers and utilizes machine learning algorithms to generate cancer-type specific GAGome scores.
Elypta is advancing a broad study program across different cancers, including multi-cancer early detection applications, with the first indication expected to be early detection of recurrence in renal cell carcinoma.
To learn more, see www.elypta.com
This will close in 0 seconds
We are a biopharmaceutical company that is driven by science, united by science, and every day, we push the boundaries of science to deliver life-changing medicines.
In Oncology, we have a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.
Our Oncology strategy is built with one goal in mind – to push the boundaries of science to change the practice of medicine and transform the lives of patients living with cancer. Our broad pipeline of next-generation medicines, together with our focus on excellence in execution, are aimed at expanding treatment options and improving outcomes for patients with solid tumours and haematological cancers.
This will close in 0 seconds
PacBio is a premier life science technology company that is designing, developing, and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. PacBio products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing and our emerging SBB® short read sequencing technologies. PacBio products address solutions across a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. In cancer research and oncology, PacBio HiFi long-read technology provides a more complete view of the cancer genome and transcriptome, enabling discovery of novel variants in all variant classes including structural variants, isoforms, and fusions, while our emerging SBB® short read sequencing technology enables highly sensitive detection of ctDNA with reduced sequencing depth in liquid biopsy applications.
This will close in 0 seconds
At Roche UK, we focus our energy and investment in developing tests and treatments that change lives and give us more quality time with the people we love. And, together with others, we’re solving healthcare’s greatest challenges; helping to achieve better results by connecting early diagnosis to targeted treatment and ongoing support.
Healthcare matters to all of us. That’s why we work hard to ensure that all our new medicines are made available to those who need them through the NHS - wherever they live, whatever their circumstances.
In 2020, more than 820 million Roche diagnostic tests were used to confirm, rule out or manage health conditions and over 712,000 patients benefited from our medicines and diabetes monitoring and insulin delivery system. During this period, we contributed £1.26 billion to the UK economy, supporting over 21,000 jobs.
Proud of what we do, we’re here because we care. In the UK we employ over 2,000 brilliant specialists who work together to transform the lives of patients and their loved ones.
That’s what makes us who we are. That’s what makes us Roche UK. For more information, please visit www.roche.co.uk.
This will close in 0 seconds
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.
For more information, please visit olink.com. Olink® is a registered trademark of Olink Proteomics AB.
This will close in 0 seconds
biomodal is an omics-based life sciences technology and analytics company delivering products that bring the dynamism of our ever-changing biology into focus. Our duet multiomics solution enables more epigenetic information from a single, low input DNA library without complex, resource intensive bioinformatics or harsh chemical treatment. Our single-base-resolution, phased sequencing approach unlocks the combinatorial power of genetic and epigenetic information in one workflow, elucidating greater biological insight within the fields of cancer, neurodegenerative disease, and ageing.
One sample, one workflow, one solution for multiomic insights
duet multiomics solution +modC simultaneously sequences genetics & epigenetics in a single workflow. See all four genetic bases (A-C-G-T) without ambiguity in C or T calls – plus modified cytosine (modC) using your existing next-generation sequencer, with results phased within a single read.
This will close in 0 seconds
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and enable earlier detection and more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 150 peer-reviewed publications that demonstrate high accuracy. Based on its deep expertise in cfDNA analysis, Natera is developing blood tests for both elevated risk multi-cancer early detection (MCED) detection and average risk colorectal (CRC) cancer detection. These assays analyze the methylation and mutation status in regions of cfDNA associated with cancer.
This will close in 0 seconds
Exact Sciences is changing lives through earlier detection and smarter answers.
Getting ahead of cancer is crucial no matter where people are in their cancer journey. From earlier cancer detection to treatment guidance and monitoring, we help people get the answers they need to make more informed decisions across the cancer continuum.
With a leading portfolio of products for earlier detection and treatment guidance — including the Cologuard® and Oncotype DX® tests — we help people face the most challenging decisions with confidence.
Our dedication to taking on the impossible fuels everything we do. We are continuously innovating, combining scientific rigor with an open-minded approach to deliver the next big thing in cancer care.
Learn more at exactsciences.com.
This will close in 0 seconds
DELFI Diagnostics (“DNA EvaLuation of Fragments for early Interception”) is developing next-generation, blood-based cancer detection tests that are accurate, accessible and deliver a new way to detect cancer. DELFI tests are built to solve the highest-burden population health issues, including in historically underserved demographics. Our science is based on fragmentomics, the discovery that cancer cells are more disorganized than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments in the blood. We combine advanced machine-learning with whole-genome sequencing data to accurately compare an individual’s cfDNA fragments against populations with and without cancer. The DELFI platform uses these millions of data points to reliably identify individuals who may have lung cancer, including early stage disease.
DELFI’s first product is a lung cancer detection test for screen-eligible individuals. Lung cancer remains the top cancer killer in the United States, with nearly 140,000 people dying from the disease each year. Low-dose CT scans have proven effective in detecting disease, yet 94% of eligible adults do not receive them. The DELFI test has a 99.7% negative predictive value, meaning that individuals who do not show signs of disease are not likely to have lung cancer found by LDCT.
This will close in 0 seconds